EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II—2020 update: treatment of relapsing and metastatic prostate cancer

P Cornford, RCN van den Bergh, E Briers… - European urology, 2021 - Elsevier
Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …

Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer—updated diagnostic utility, sensitivity, specificity, and …

M Perera, N Papa, M Roberts, M Williams, C Udovicich… - European urology, 2020 - Elsevier
Context Accurate staging of high-risk localised, advanced, and metastatic prostate cancer is
becoming increasingly more important in guiding local and systemic treatment. Gallium-68 …

Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial

WP Fendler, J Calais, M Eiber, RR Flavell… - JAMA …, 2019 - jamanetwork.com
Importance In retrospective studies, 68 Ga-PSMA-11 positron emission tomographic (PET)
imaging improves detection of biochemically recurrent prostate cancer compared with …

Cohort study of oligorecurrent prostate cancer patients: oncological outcomes of patients treated with salvage lymph node dissection via prostate-specific membrane …

S Knipper, MM Irai, R Simon, D Koehler, I Rauscher… - European Urology, 2023 - Elsevier
Background In a subset of patients with recurrent oligometastatic prostate cancer (PCa)
salvage surgery with prostate-specific membrane antigen (PSMA)-targeted radioguidance …

Lutetium-177-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer: a prospective pilot study

BM Privé, SMB Peters, CHJ Muselaers, IM van Oort… - Clinical Cancer …, 2021 - AACR
Abstract Purpose:[177Lu] Lu-PSMA-617 radioligand therapy (177Lu-PSMA) is a novel
treatment for metastatic castration-resistant prostate cancer (mCRPC), which could also be …

Robot-assisted prostate-specific membrane antigen–radioguided salvage surgery in recurrent prostate cancer using a DROP-IN gamma probe: the first prospective …

HA de Barros, MN van Oosterom, ML Donswijk… - European Urology, 2022 - Elsevier
Background It has been proven that intraoperative prostate-specific membrane antigen
(PSMA)-targeted radioguidance is valuable for the detection of prostate cancer (PCa) …

Long-term outcomes of salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy: not as good as previously thought

CA Bravi, N Fossati, G Gandaglia, N Suardi… - European urology, 2020 - Elsevier
Background Long-term outcomes of patients treated with salvage lymph node dissection
(sLND) for nodal recurrence of prostate cancer (PCa) remain unknown. Objective To …

Metastasis-directed therapy in treating nodal oligorecurrent prostate cancer: a multi-institutional analysis comparing the outcome and toxicity of stereotactic body …

E De Bleser, BA Jereczek-Fossa, D Pasquier, T Zilli… - European urology, 2019 - Elsevier
Background Stereotactic body radiotherapy (SBRT) and elective nodal radiotherapy (ENRT)
are being investigated as metastasis-directed treatments in oligorecurrent prostate cancer …

OLIGOPELVIS GETUG P07, a multicenter phase II trial of combined high-dose salvage radiotherapy and hormone therapy in oligorecurrent pelvic node relapses in …

S Supiot, L Vaugier, D Pasquier, X Buthaud, N Magné… - European Urology, 2021 - Elsevier
Background Oligorecurrent pelvic nodal relapse in prostatic cancer is a challenge for
regional salvage treatments. Androgen depriving therapies (ADTs) are a mainstay in …

Management of patients with node-positive prostate cancer at radical prostatectomy and pelvic lymph node dissection: a systematic review

G Marra, M Valerio, I Heidegger, I Tsaur… - European urology …, 2020 - Elsevier
Context Optimal management of prostate cancer (PCa) patients with lymph node invasion at
radical prostatectomy and pelvic lymph node dissection still remains unclear. Objective To …